Dr Reddy’s inks pact with Gilead to manufacture, market Remdesivir in India

Dr Reddy’s Laboratories has entered into a non-exclusive licensing agreement with US-based Gilead Sciences to register, manufacture and sell Gilead’s investigational drug Remdesivir, a potential treatment for Covid-19, in 127 countries, including India.

It will receive technology transfer from Gilead for manufacturing this drug. Dr Reddy’s would need to do the manufacturing scale up and obtain regulatory approval for marketing this drug in the respective countries.

Gilead Sciences has already signed 22 non-exclusive voluntary agreements with six generic pharmaceutical companies in India and Pakistan to manufacture and distribute remdesivir.